The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors.
 
Alison M. Schram
No Relationships to Disclose
 
Alexander E. Drilon
Honoraria - Foundation Medicine; Medscape; MORE Health; OncLive; Peerview; PeerVoice; Physicans' Education Resource; Research to Practice; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Exelixis; Genentech/Roche; Helsinn Therapeutics; Hengrui Therapeutics; Ignyta; Lilly; Loxo; MORE Health; Pfizer; Takeda/Millennium; TP Therapeutics; Tyra Biosciences; Verastem; Verastem
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - GlaxoSmithKline; Merck; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Teresa Macarulla
Consulting or Advisory Role - Baxalta; Baxter; Celgene; Incyte; Ipsen; Lilly; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Shire
Research Funding - Agios (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); Merrimack (Inst); Millennium (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Merck; Sanofi; SERVIER
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); AstraZeneca (I); Bayer (I); BeiGene (I); Berry Genomics (I); Celgene (I); CytomX Therapeutics; Debiopharm Group (I); Debiopharm Group (I); Eisai (I); Exelixis/Ipsen (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Incyte (I); Janssen; LAM Therapeutics (I); Lilly (I); Loxo; Merck; Minapharma (I); QED Therapeutics (I); RedHill Biopharma (I); Sillajen (I); SOBI; Targovax; Yiviva (I)
Research Funding - AstraZeneca/MedImmune (Inst)
 
Jordi Rodon
No Relationships to Disclose
 
Brian M. Wolpin
Honoraria - Celgene; G1 Therapeutics
Consulting or Advisory Role - BioLineRx; Celgene; G1 Therapeutics; Genentech; GRAIL; GRAIL
Research Funding - Celgene; Lilly
 
Sai-Hong Ignatius Ou
Stock and Other Ownership Interests - Turning Point Therapeutics
Honoraria - ARIAD/Takeda; AstraZeneca; Foundation Medicine; Genentech/Roche; Merck; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Pfizer; Roche/Genentech; Takeda; TP Therapeutics
Speakers' Bureau - AstraZeneca; Genentech; Takeda
Research Funding - ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Ignyta (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche Pharma AG (Inst)
 
Dong-Wan Kim
Research Funding - Alpha Biopharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Hanmi (Inst); Janssen (Inst); Merus (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst); TP Therapeutics (Inst); Xcovery (Inst); Yuhan (Inst)
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo
 
James C. Yang
Research Funding - Kite/Gilead (Inst)
Patents, Royalties, Other Intellectual Property - Royalties on inventions may go to my institution (NCI) which may pass a portion (anonymously) to me.
 
Justina Yick Ching Lam
No Relationships to Disclose
 
Andrea Varga
No Relationships to Disclose
 
Joop De Langen
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); MSD Oncology (Inst); Roche (Inst)
 
Petronella Witteveen
No Relationships to Disclose
 
Valentina Boni
Honoraria - IDEAYA Biosciences; Loxo
Consulting or Advisory Role - Guidepoint Global; OncoArt
Speakers' Bureau - Solti
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Incyte (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - START
 
Giulio Cerea
No Relationships to Disclose
 
Michaël Duruisseaux
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
 
Stephen V. Liu
Consulting or Advisory Role - Apollomics; ARIAD; AstraZeneca; Bristol-Myers Squibb; Celgene; G1 Therapeutics; Genentech; Guardant Health; HERON; Ignyta; Inivata; Janssen Oncology; Lilly; Loxo; Merck; MSD Oncology; Pfizer; PharmaMar; Regeneron; Roche; Taiho Pharmaceutical; Takeda; Tempus
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Debiopharm Group (Inst); Esanex (Inst); Genentech/Roche (Inst); Ignyta (Inst); Lilly (Inst); Lycera (Inst); Merck (Inst); Molecular Partners (Inst); OncoMed (Inst); Pfizer (Inst); Rain Therapeutics (Inst); Threshold Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Roche/Genentech
 
Ernesto Wasserman
Employment - Merus NV
Stock and Other Ownership Interests - Merus NV
 
Josep Tabernero
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; BeiGene; Biocartis; Boehringer Ingelheim; Chugai Pharma; Foundation Medicine; Genentech; Genmab; HalioDx; Halozyme; Imugene; Inflection Biosciences; Ipsen; Kura Oncology; Lilly; Menarini; Merck Serono; Merrimack; Merus; Molecular Partners; MSD; Novartis; Peptomyc; Pfizer; Pharmacyclics; ProteoDesign; Rafael Pharmaceuticals; Roche; Roche; Sanofi; Seagen; Seagen; Servier; Symphogen; Taiho Pharmaceutical; VCN Biosciences